There are currently 695 clinical trials in Orlando, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including AdventHealth Orlando, GSK Investigational Site, Orlando Clinical Research Center and Nemours Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Together After Cancer
NCT05645471
Recruiting
To evaluate the impact of an adapted online, self-help relationship intervention (supplemented with brief coach calls) for survivors of breast cancer and their partners. Couples will be randomized to receive either the online intervention (Together after Cancer) or usual care (UC) and assessed at baseline, end of the program, and 3 months after randomization.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/18/2023
Locations: AdventHealth, Orlando, Florida
Conditions: Breast Cancer, Quality of Life, Communication
Register for Updates
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. Until recently, the mainstay of treatment for these patients was supportive medical care. Howe... Read More
Gender:
All
Ages:
All
Trial Updated:
04/18/2023
Locations: Adventist Health System - Florida, Orlando, Florida
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates
Screening for High Frequency Malignant Disease
NCT05117840
Recruiting
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/10/2023
Locations: Central Florida Pulmonary Group, P.A., Orlando, Florida +2 locations
Conditions: Lung Cancer
Register for Updates
Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease
NCT05379348
Recruiting
The purpose of this study is to investigate how we can detect Alzheimer's disease early by using an online memory test and a simple blood test. These new methods for early diagnosis could allow people to begin treatment sooner, with the potential to improve the lives of millions of people.
Gender:
All
Ages:
65 years and above
Trial Updated:
04/03/2023
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Alzheimer Disease
Register for Updates
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
NCT04053673
Recruiting
RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1 interferon) that tells the immune system that something is wrong and to kill the cell. RBN-2397 has been shown in animal studies to inhibit tumor growth and also shuts down the "don't kill me" signal the tumor is sending to evade the immune system. As a PARP7 inhibitor RBN-2397 is... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida
Conditions: Solid Tumor, Adult
Register for Updates
Using a mHealth Intervention to Promote Physical Activity in Phase III Cardiac Rehabilitation Clients
NCT05795036
Recruiting
In this study, we will implement a pilot project of using activity tracker (i.e., Fitbit) with phase III CR clients. The study will record the clients' daily steps and sleep patterns for 8 consecutive weeks in natural settings. Two specific aims are identified for this project: Develop an intervention protocol using mHealth to promote Phase III CR clients' self-monitoring of PA. Examine the efficacy of the intervention on clients' PA, sleep patterns, functional capacity and QoL.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
03/21/2023
Locations: AdventHealth University, Orlando, Florida
Conditions: Cardiac Rehabilitation, Physical Activity
Register for Updates
Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites
NCT04288921
Recruiting
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx Influenza A/B + RSV Test at Point of Care Testing Sites
Gender:
All
Ages:
All
Trial Updated:
03/10/2023
Locations: Nona Pediatric Center, Orlando, Florida
Conditions: Influenza, Human, Respiratory Syncytial Virus Infections
Register for Updates
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
NCT02235857
Recruiting
Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipid... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
03/07/2023
Locations: Nemours Children's Health, Orlando, Florida
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, Orlando, Florida
Conditions: Cystic Fibrosis
Register for Updates
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643
Recruiting
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: University of Florida Cancer Center at Orlando Health, Orlando, Florida
Conditions: HER2-negative Breast Cancer
Register for Updates
Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care
NCT04299022
Recruiting
Prospective registry and retrospective data collection study to assess the efficacy and safety of Vivigen Cellular Bone Matrix (Vivigen) in orthopaedic trauma patients who require bone grafting in the acute, delayed, non-union fracture as well as use in fusion procedure settings.
Gender:
All
Ages:
All
Trial Updated:
03/01/2023
Locations: OrlandoHealth, Orlando, Florida
Conditions: Fractures, Bone, Nonunion of Fracture, Fractures, Open, Fractures, Ununited, Fracture, Tibial, Fracture of Femur, Fracture Arm
Register for Updates
Randomized Therapy In Status Epilepticus
NCT04391569
Recruiting
This study will evaluate the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).
Gender:
All
Ages:
12 years and above
Trial Updated:
02/22/2023
Locations: Marinus Research Site, Orlando, Florida
Conditions: Status Epilepticus
Register for Updates